615 related articles for article (PubMed ID: 32504663)
1. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
2. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue.
Mak LY; Lee CH; Cheung KS; Wong DK; Liu F; Hui RW; Fung J; Xu A; Lam KS; Yuen MF; Seto WK
Liver Int; 2019 Jul; 39(7):1217-1225. PubMed ID: 30912255
[TBL] [Abstract][Full Text] [Related]
3. Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B.
Seto WK; Hui RWH; Mak LY; Fung J; Cheung KS; Liu KSH; Wong DK; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):575-583.e2. PubMed ID: 28970146
[TBL] [Abstract][Full Text] [Related]
4. No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Viral Hepat; 2021 Nov; 28(11):1545-1553. PubMed ID: 34382730
[TBL] [Abstract][Full Text] [Related]
5. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval.
Mak LY; Seto WK; Hui RW; Fung J; Wong DK; Lai CL; Yuen MF
J Viral Hepat; 2019 Jul; 26(7):818-827. PubMed ID: 30895682
[TBL] [Abstract][Full Text] [Related]
6. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors.
Yu MW; Lin CL; Liu CJ; Huang YW; Hu JT; Wu WJ; Wu CF
J Formos Med Assoc; 2022 Aug; 121(8):1478-1487. PubMed ID: 34764005
[TBL] [Abstract][Full Text] [Related]
7. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Li B; Cheung KS; Yuen MF; Seto WK
Hepatol Int; 2021 Aug; 15(4):901-911. PubMed ID: 34152534
[TBL] [Abstract][Full Text] [Related]
8. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study.
Hui RWH; Seto WK; Cheung KS; Mak LY; Liu KSH; Fung J; Wong DK; Lai CL; Yuen MF
J Viral Hepat; 2018 Jan; 25(1):97-104. PubMed ID: 28772340
[TBL] [Abstract][Full Text] [Related]
9. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
[TBL] [Abstract][Full Text] [Related]
10. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
11. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without.
Chu CM; Lin DY; Liaw YF
Dig Dis Sci; 2013 Jan; 58(1):275-81. PubMed ID: 22903182
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liu CH; Liao SH; Hong CM; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Clin Gastroenterol Hepatol; 2024 Mar; 22(3):581-590.e6. PubMed ID: 37871842
[TBL] [Abstract][Full Text] [Related]
13. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.
Gaia S; Carenzi S; Barilli AL; Bugianesi E; Smedile A; Brunello F; Marzano A; Rizzetto M
J Hepatol; 2011 Jan; 54(1):64-71. PubMed ID: 20932598
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection.
Sefa Sayar M; Bulut D; Acar A
Arab J Gastroenterol; 2023 Feb; 24(1):11-15. PubMed ID: 35688683
[TBL] [Abstract][Full Text] [Related]
15. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
[TBL] [Abstract][Full Text] [Related]
16. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
Cai YJ; Dong JJ; Wang XD; Huang SS; Chen RC; Chen Y; Wang YQ; Song M; Chen YP; Li Z; Zhou MT; Shi KQ
J Viral Hepat; 2017 Nov; 24(11):1005-1015. PubMed ID: 28419755
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C.
Wang CL; Huang CH; Wu VC; Wu CL; Huang YT; Chang SH
Dig Dis Sci; 2023 Jun; 68(6):2747-2756. PubMed ID: 37071242
[TBL] [Abstract][Full Text] [Related]
19. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study.
Yi S; Ren G; Zhu Y; Cong Q
Virol J; 2024 Jan; 21(1):22. PubMed ID: 38243304
[TBL] [Abstract][Full Text] [Related]
20. Association of Coexistent Hepatitis B Surface Antigen and Antibody With Severe Liver Fibrosis and Cirrhosis in Treatment-Naive Patients With Chronic Hepatitis B.
Wang J; Ding W; Liu J; Liu Y; Yan X; Xia J; Wu W; Jia B; Chen Y; Gao D; Hong S; Wang X; Wang L; Tong X; Yin S; Zhang Z; Li J; Huang R; Wu C
JAMA Netw Open; 2022 Jun; 5(6):e2216485. PubMed ID: 35696167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
